Giancarlo Castaman
University of Florence
435 Papers
3.6K Citations
Giancarlo Castaman is an academic researcher from University of Florence. The author has contributed to research in topics: Medicine & Von Willebrand disease. The author has an hindex of 60, co-authored 389 publications. Previous affiliations of Giancarlo Castaman include UniFi & University of Milan.
Chat about Author
Papers
Congenital afibrinogenemia: Successful prevention of recurrent hemoperitoneum during ovulation by oral contraceptive
Abstract: I . Tsutani H, Sugiyama T, Shimizu S, Iwasaki H, Ueda T, Ozaki K, Konda S , Nakamura T Discordant LFAIIICAM1 expression in a case of secondary plasma cell leukemia associated with subcutaneous plasmacytoma. Am J Hematol42:299304, 1993. 2. Ashmann WM, Lokhorst HM, Dekker AW, Bloem AC: Lymphocyte functionassociated antigen-I expression on plasma cell correlates with tumor growth in multiple myloma. Blood 792068-2075, 1992.
Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease
TL;DR: A subgroup of patients with severe vWD shows an increase of VIII:C after DDAVP, and a test infusion with this agent is advisable in patients withsevere vWD before considering treatment with VIII/vWF concentrates.
The spectrum of factor XI deficiency in Italy.
Giancarlo Castaman,Sofia H. Giacomelli,Sonia Caccia,F. Riccardi,G. Rossetti,Alfredo Dragani,Anna Chiara Giuffrida,Chiara Biasoli,Stefano Duga +8 more
TL;DR: At variance with other populations, no single major founder effect is present in Italian patients with FXI deficiency, and a total of 34 heterozygous relatives were identified, including 10 novel mutations.
Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study.
Eugenia Biguzzi,Cristina Razzari,Cristina Razzari,David A. Lane,Giancarlo Castaman,Antonio Cappellari,Paolo Bucciarelli,Gessica Fontana,Maurizio Margaglione,Giovanna D'Andrea,Rachel E. Simmonds,Suely M. Rezende,Roger J. S. Preston,Domenico Prisco,Elena M. Faioni +14 more
TL;DR: PROSIT showed that dysfunctional variants causing PS deficiency are more common than expected and confirmed that PS deficiency is associated with increased thrombotic risk, although risk assessment is complicated by molecular heterogeneity.
•Journal Article
Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol.
TL;DR: The clinical usefulness of VA and Azp is very limited and burdened by severe side-effects, and Danazol seems to be safer but no more effective and its long-term toxicity is not known.